No benefit from ramucirumab in first-line chemotherapy?
Sign Up to like & getrecommendations! Published in 2017 at "Translational gastroenterology and hepatology"
DOI: 10.21037/tgh.2017.03.18
Abstract: Ramucirumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human vascular endothelial growth factor receptor-2 (VEGFR-2). It prevents the binding of VEGFR-2 with its ligands including VEGF-A, VEGF-C, and VEGF-D. Thus, receptor activation… read more here.
Keywords: first line; phase iii; benefit ramucirumab; ramucirumab ... See more keywords